Cost to bring biopharmaceutical assets in mid cap companies to market 2013-2020
This statistic shows the cost to bring a biopharmaceutical asset to market among mid-to-large cap biopharma companies from 2013 to 2020. According to the data, the cost to bring an asset to market was highest in 2018, with some 2.8 billion U.S. dollars.